Search

Your search keyword '"Viennot, Stephanie"' showing total 123 results

Search Constraints

Start Over You searched for: Author "Viennot, Stephanie" Remove constraint Author: "Viennot, Stephanie"
123 results on '"Viennot, Stephanie"'

Search Results

2. Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID

3. Adalimumab in Biologic-naïve Patients With Crohn’s Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID

6. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

8. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

9. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

10. COMPARISON OF NORMAL VS INTENSIFIED VACCINE REGIMENS AGAINST PNEUMOCOCCUS IN CD PATIENTS UNDER BIOTHERAPY: A PROSPECTIVE, MULTICENTER, RANDOMIZED, OPEN-LABEL, PNEUMOMICI STUDY

11. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID

12. Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study

13. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

14. A Scoring System to Determine Patients’ Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis

15. Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group

16. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus

17. Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study

19. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis

21. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease

22. Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission

23. Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases

24. Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID

25. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

26. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

27. Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation

28. Prevalence and determinants of fatigue in patients with IBD: a cross-sectional survey from the GETAID

29. Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID

30. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID

31. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study

32. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

33. Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases

34. 887: WITHDRAWAL OF INFLIXIMAB OR ANTI-METABOLITE THERAPY IN CROHN'S DISEASE PATIENTS IN SUSTAINED REMISSION ON COMBINATION THERAPY: A RANDOMIZED UNBLINDED CONTROLLED TRIAL (SPARE)

35. Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

36. Su1490: COVID-19: A PREVALENCE RATE TWO TIMES LOWER THAN THAT OF THE GENERAL POPULATION IN FRENCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INTRAVENOUS BIOLOGIC AGENTS

37. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

38. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment

40. The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease

41. Determinants of IBD-related disability: a cross-sectional survey from the GETAID

42. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study

43. 457 ADALIMUMAB FOR PATIENTS WITH CROHN'S DISEASE COMPLICATED BY INTRA-ABDOMINAL ABSCESS : LONG-TERM RESULTS OF THE MICA STUDY

44. Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group

45. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus

46. Ustekinumab for Perianal Crohn's Disease

47. Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn’s Disease: A Multicentre Study

48. Sa1744 IMPACT OF LINE OF THERAPY, THERAPEUTIC ESCALATION OR DE-ESCALATION ON ACCEPTABILITY OF TREATMENT REGIMEN IN INFLAMMATORY BOWEL DISEASE: A SUB-ANALYSIS FROM THE PROSPECTIVE NATIONWIDE STUDY ACCEPT2.

49. Mo1873 WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

50. Sa1743 ACCEPTABILITY OF TREATMENT REGIMEN IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM A PROSPECTIVE NATIONWIDE STUDY (ACCEPT2).

Catalog

Books, media, physical & digital resources